Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Arthritis Rheumatol. 2020 Aug 9;72(10):1707–1720. doi: 10.1002/art.41383

Figure 4. Nrf2 activation changes the phenotype of NCM.

Figure 4.

A, Mice were injected with pristane plus CDDO-Im as in figure 2, or vehicle (Control) for 14-d. Surface staining (flow cytometry) of PEC for Ly6C, PDCA-1 and CD169 on CM and NCM and for CD138 on NCM. B, Wild-type B6 (WT) and B6 Nrf2−/− mice were injected with pristane and 14-d later PEC were analyzed by flow cytometry. Surface staining for Ly6C, PDCA-1 and CD169 on CM and NCM and CD138 expression level on NCM. C, Mice (4-5/group) were injected with pristane plus brusatol as in figure 3 or vehicle (Control) for 9-d. Left, surface staining of PEC for Ly6C and CD138 on NCM (left). Right, percentages of CM and NCM in CD11b+Ly6G− cells (right). * P < 0.05, ** P < 0.01, *** P < 0.001 (Student t-test).